These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 23511167)

  • 1. Direct reprogramming en route to neoplastic transformation.
    Nemajerova A; Petrenko O
    Cell Cycle; 2013 Apr; 12(7):1013-4. PubMed ID: 23511167
    [No Abstract]   [Full Text] [Related]  

  • 2. Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes.
    Sasaki R; Narisawa-Saito M; Yugawa T; Fujita M; Tashiro H; Katabuchi H; Kiyono T
    Carcinogenesis; 2009 Mar; 30(3):423-31. PubMed ID: 19126650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways.
    Buganim Y; Solomon H; Rais Y; Kistner D; Nachmany I; Brait M; Madar S; Goldstein I; Kalo E; Adam N; Gordin M; Rivlin N; Kogan I; Brosh R; Sefadia-Elad G; Goldfinger N; Sidransky D; Kloog Y; Rotter V
    Cancer Res; 2010 Mar; 70(6):2274-84. PubMed ID: 20197462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status.
    Crespo NC; Delarue F; Ohkanda J; Carrico D; Hamilton AD; Sebti SM
    Cell Death Differ; 2002 Jul; 9(7):702-9. PubMed ID: 12058275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
    Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
    Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PRAK is essential for ras-induced senescence and tumor suppression.
    Sun P; Yoshizuka N; New L; Moser BA; Li Y; Liao R; Xie C; Chen J; Deng Q; Yamout M; Dong MQ; Frangou CG; Yates JR; Wright PE; Han J
    Cell; 2007 Jan; 128(2):295-308. PubMed ID: 17254968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence.
    Zou X; Ray D; Aziyu A; Christov K; Boiko AD; Gudkov AV; Kiyokawa H
    Genes Dev; 2002 Nov; 16(22):2923-34. PubMed ID: 12435633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation.
    Kawauchi K; Araki K; Tobiume K; Tanaka N
    Nat Cell Biol; 2008 May; 10(5):611-8. PubMed ID: 18391940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells.
    Luu C; Heinrich EL; Duldulao M; Arrington AK; Fakih M; Garcia-Aguilar J; Kim J
    PLoS One; 2013; 8(8):e70604. PubMed ID: 23936455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C/EBPβ deletion in oncogenic Ras skin tumors is a synthetic lethal event.
    Messenger ZJ; Hall JR; Jima DD; House JS; Tam HW; Tokarz DA; Smart RC
    Cell Death Dis; 2018 Oct; 9(11):1054. PubMed ID: 30323292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYC and RAS are unable to cooperate in overcoming cellular senescence and apoptosis in normal human fibroblasts.
    Zhang F; Zakaria SM; Högqvist Tabor V; Singh M; Tronnersjö S; Goodwin J; Selivanova G; Bartek J; Castell A; Larsson LG
    Cell Cycle; 2018; 17(24):2697-2715. PubMed ID: 30526305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations.
    Sato M; Larsen JE; Lee W; Sun H; Shames DS; Dalvi MP; Ramirez RD; Tang H; DiMaio JM; Gao B; Xie Y; Wistuba II; Gazdar AF; Shay JW; Minna JD
    Mol Cancer Res; 2013 Jun; 11(6):638-50. PubMed ID: 23449933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tbx3 impinges on the p53 pathway to suppress apoptosis, facilitate cell transformation and block myogenic differentiation.
    Carlson H; Ota S; Song Y; Chen Y; Hurlin PJ
    Oncogene; 2002 May; 21(24):3827-35. PubMed ID: 12032820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations.
    Caulin C; Nguyen T; Lang GA; Goepfert TM; Brinkley BR; Cai WW; Lozano G; Roop DR
    J Clin Invest; 2007 Jul; 117(7):1893-901. PubMed ID: 17607363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
    Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
    BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma.
    Jazaeri AA; Bryant JL; Park H; Li H; Dahiya N; Stoler MH; Ferriss JS; Dutta A
    Neoplasia; 2011 Oct; 13(10):899-911. PubMed ID: 22028616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unraveling human tumor suppressor pathways: a tale of the INK4A locus.
    Voorhoeve PM; Agami R
    Cell Cycle; 2004 May; 3(5):616-20. PubMed ID: 15044859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
    DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
    Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.